Veracyte | VCYT - Current Liabilities


Veracyte reported $84.21M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Agenus USD 231.82M 17.42M Jun/2026
Agilent USD 2.29B 20M Jun/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 311.34M 27.99M Sep/2026
Bruker USD 1.17B 32.6M Sep/2026
Heron Therapeutics USD 89.85M 2.3M Sep/2026
Illumina USD 1.16B 422M Sep/2026
Intrexon USD 23.02M 38K Jun/2024
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Laboratory Of America USD 2.82B 695M Sep/2026
Ligand Pharmaceuticals USD 500.57M 453.83M Sep/2026
Myriad Genetics USD 130.7M 500K Jun/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Siemens EUR 47.56B 2.45B Sep/2026
Sonic Healthcare AUD 2.23B 92.84M Dec/2024
Thermo Fisher Scientific USD 14.17B 899M Sep/2026
Veracyte USD 84.21M 21.47M Sep/2026
Waters USD 2.4B 126M Jun/2026